Published in Br J Cancer on April 20, 2010
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Bioanalytical method validation--a revisit with a decade of progress. Pharm Res (2000) 6.83
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res (2003) 4.54
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal (2000) 3.72
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet (1992) 2.88
Platelets and cancer. Lancet Oncol (2002) 2.51
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15
Protein aggregation: pathways, induction factors and analysis. J Pharm Sci (2009) 2.04
Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods (2008) 2.03
Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther (2007) 1.83
Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 1.82
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods (2009) 1.81
Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res (2004) 1.72
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol (2008) 1.51
Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin Vaccine Immunol (2007) 1.50
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res (2005) 1.44
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer (2005) 1.36
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol (2007) 1.19
Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn (2007) 1.17
Protein microarray platform for the multiplex analysis of biomarkers in human sera. J Immunol Methods (2006) 1.13
A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One (2009) 1.09
Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol (2005) 1.04
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin. J Biol Chem (2009) 0.97
The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) (2009) 0.94
Effects of pH and arginine on the solubility and stability of a therapeutic protein (Fibroblast Growth Factor 20): relationship between solubility and stability. Curr Pharm Biotechnol (2009) 0.90
Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev (2006) 0.90
Sample handling and stability of hepatocyte growth factor in blood samples. Cytokine (2002) 0.88
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest (2008) 0.86
Enhanced stability of recombinant keratinocyte growth factor by mutagenesis. Protein Eng Des Sel (2006) 0.84
Assignment of intrachain disulfide bonds in platelet-derived growth factor B-chain. J Biol Chem (1993) 0.82
Some important considerations for validation of ligand-binding assays. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.82
Establishing and evaluating QC acceptability criteria. MLO Med Lab Obs (1994) 0.79
Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies. AAPS J (2007) 0.77
Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol (2008) 0.76
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Experimental annotation of the human genome using microarray technology. Nature (2001) 10.39
Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature (1994) 4.92
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res (2001) 3.45
Functional food properties of non-digestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095). Br J Nutr (1999) 3.40
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc Sci Med (1994) 3.05
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
IgA subclasses in various secretions and in serum. Immunology (1982) 2.43
Low back pain. J R Coll Gen Pract (1968) 2.39
Broadband observations of the naked-eye gamma-ray burst GRB 080319B. Nature (2008) 2.16
A randomized trial of the cost effectiveness of VA hospital-based home care for the terminally ill. Health Serv Res (1992) 2.09
The RAD50 gene, a member of the double strand break repair epistasis group, is not required for spontaneous mitotic recombination in yeast. Curr Genet (1990) 1.93
Effectiveness of team-managed home-based primary care: a randomized multicenter trial. JAMA (2000) 1.89
Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest (1983) 1.86
Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest (1982) 1.84
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods (2009) 1.81
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci (1996) 1.80
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst (2000) 1.77
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Emergence of artistic talent in frontotemporal dementia. Neurology (1998) 1.70
Crystal structure of nitrile hydratase reveals a novel iron centre in a novel fold. Structure (1997) 1.68
Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol (1997) 1.62
Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem (2001) 1.61
Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol (2003) 1.61
Intra-tumoural microvessel density in human solid tumours. Br J Cancer (2002) 1.60
Nature and origin of the proteins of bile. I. A comparative analysis of serum and bile proteins in man. Eur J Clin Invest (1974) 1.59
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res (1993) 1.59
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry (2008) 1.51
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Apoptosis and cancer chemotherapy. Trends Cell Biol (2001) 1.48
Ocular manifestations of equine motor neuron disease. Equine Vet J (1999) 1.47
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer (2002) 1.45
Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest (1984) 1.44
Primary renal hypoplasia in humans and mice with PAX2 mutations: evidence of increased apoptosis in fetal kidneys of Pax2(1Neu) +/- mutant mice. Hum Mol Genet (2000) 1.44
Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci (1991) 1.44
The structure of normal human attention: The Test of Everyday Attention. J Int Neuropsychol Soc (1996) 1.42
In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry (2000) 1.41
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J Virol (1997) 1.38
Origin and nature of the proteins of bile. II. A comparative analysis of serum, hepatic lymph and bile proteins in the dog. Eur J Clin Invest (1974) 1.38
Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci (1993) 1.37
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer (2005) 1.36
Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci (1990) 1.34
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem (1997) 1.34
Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J (2001) 1.32
Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol (2008) 1.32
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
The unusual γ-ray burst GRB 101225A from a helium star/neutron star merger at redshift 0.33. Nature (2011) 1.31
The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) (2000) 1.29
Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat. Biopharm Drug Dispos (1985) 1.29
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death. Cell Death Differ (2003) 1.27
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene (2008) 1.26
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol (1999) 1.24
Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene (2001) 1.23
Examination gloves as barriers to hand contamination in clinical practice. JAMA (1993) 1.23
The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) (2003) 1.23
Reversible dementia. Illustrative cases, definition, and review. JAMA (1980) 1.20
A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol (2006) 1.20
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res (1993) 1.20
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol (2007) 1.19
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer (2006) 1.18
A giant gamma-ray flare from the magnetar SGR 1806-20. Nature (2005) 1.17
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene (2009) 1.17
Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol (1998) 1.17
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol (1996) 1.15
Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Mol Cell Biol (2001) 1.13
An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant (2010) 1.13
Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor. J Gen Virol (1998) 1.13
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Perceived organizational support, discretionary treatment, and job satisfaction. J Appl Psychol (1997) 1.12
Molecular characterization of the Fusarium graminearum species complex in Japan. Phytopathology (2008) 1.12
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol (2000) 1.10
The maxillofacial unit. Ann R Coll Surg Engl (1975) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer (2000) 1.08
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer (2000) 1.08
The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr (2010) 1.08
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer (2010) 1.08